Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management
BJU International · 2025
DOI: 10.1111/bju.16860 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Yuma Goto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Denosumab, Bone Neoplasms, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the cumulative incidence of medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer and bone metastases receiving long‐term denosumab treatment, and also the occurrence of severe MRONJ and risk factors associated with the development of both MRONJ and severe MRONJ. Patients and Methods This retrospective study included 624 patients with prostate cancer and bone metastases treated with denosumab between January 2015 and December 2024. Patients without bone metastasis or with insufficient clinical data were excluded. The study assessed the cumulative incidence of MRONJ, as well as risk factors associated with MRONJ of any stage and severe MRONJ (Stage ≥2). Cox regression analysis was used to identify independent risk factors.
Results
The cumulative incidence of MRONJ at 1, 2, 3, and 6 years was 4.6%, 9.6%, 20.3%, and 51.9%, respectively. For severe MRONJ, the corresponding rates were 2.4%, 6.7%, 13.1%, and 27.9%, respectively. Multivariate analysis identified the following independent risk factors for MRONJ: extent of disease grade ≥3 (hazard ratio [HR] 2.00, P = 0.009), use of anticoagulants and/or antiplatelets (HR 2.08, P = 0.026), and a history of dental treatment within the past 6 months (HR 2.29, P = 0.003). Denosumab administration at intervals >1 month was associated with a reduced risk (HR 0.46, P = 0.041).
Conclusion
This study demonstrates that long‐term denosumab treatment in patients with prostate cancer and bone metastases is associated with a substantial cumulative incidence of MRONJ. Key risk factors were identified, along with a modifiable factor that may reduce risk. These findings suggest that adjusting denosumab dosing schedules could help mitigate MRONJ risk, underscoring the need for personalised treatment plans and early preventive strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Jikei the 3rd Hospital, Tokyo, Japan.
- Department of Urology, JR Tokyo General Hospital, Tokyo, Japan.
- Department of Urology, Machida Municipal Hospital, Tokyo, Japan.
- Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan.
- Department of Urology, Atsugi City Hospital, Atsugi, Kanagawa, Japan.
ORCID-Profile: Fumihiko Urabe, Wataru Fukuokaya, Takafumi Yanagisawa, Jun Miki
Zitieren
APA
Goto, Y., Urabe, F., Ogihara, Y., Nakata, M., Nakano, J., Fujiwara, K., Hashimoto, M., Koike, Y., Iwamoto, Y., Miyajima, K., Fukuokaya, W., Iwatani, K., Imai, Y., Inaba, Y., Ito, K., Yanagisawa, T., Murakami, M., Tashiro, K., Watanabe, K., …, & JIKEI‐YAYOI Collaborative Group (2025). Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management. BJU International. https://doi.org/10.1111/bju.16860
Vancouver
Goto Y, Urabe F, Ogihara Y, Nakata M, Nakano J, Fujiwara K, et al. Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management. BJU International. 2025. doi:10.1111/bju.16860
BibTeX
@article{Goto2025,
author = {Goto, Yuma and Urabe, Fumihiko and Ogihara, Yue and Nakata, Mana and Nakano, Juria and Fujiwara, Kensuke and Hashimoto, Masaki and Koike, Yuhei and Iwamoto, Yuya and Miyajima, Keiichiro and Fukuokaya, Wataru and Iwatani, Kosuke and Imai, Yu and Inaba, Yuzo and Ito, Kagenori and Yanagisawa, Takafumi and Murakami, Masaya and Tashiro, Kojiro and Watanabe, Katsuhito and Miki, Jun and Kimura, Takahiro and JIKEI‐YAYOI Collaborative Group, JIKEI‐YAYOI Collaborative Group},
title = {Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16860}
}
EUVIMED